Hubert Joly - Johnson Johnson Independent Director
| JNJ Stock | USD 154.26 1.24 0.80% |
Director
Hubert Joly is Independent Director of Johnson Johnson since 2019.
| Age | 61 |
| Tenure | 5 years |
| Address | One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933 |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has Return on Asset of 0.084 % which means that on every $100 spent on assets, it made $0.084 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2089 %, implying that it generated $0.2089 on every 100 dollars invested. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Johnson Johnson's Return On Tangible Assets are relatively stable compared to the past year. Return On Capital Employed is expected to hike to 0.25 this year, although the value of Return On Assets will most likely fall to 0.14. At this time, Johnson Johnson's Total Current Liabilities is relatively stable compared to the past year. Liabilities And Stockholders Equity is expected to hike to about 175.9 B this year, although the value of Change To Liabilities is projected to rise to (962.5 M).Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Carlos Sepulveda | Cinemark Holdings | 63 | |
| Mary Coe | Merck Company | 54 | |
| Suzanne Johnson | Pfizer Inc | 63 | |
| Yunus Suleman | Gold Fields Ltd | 62 | |
| Peter Wendell | Merck Company | 70 | |
| Thomas Coleman | Dorian LPG | 54 | |
| Steven Reid | Gold Fields Ltd | 64 | |
| Patricia Russo | Merck Company | 68 | |
| Steven Rosenberg | Cinemark Holdings | 62 | |
| Dan Littman | Pfizer Inc | 68 | |
| Paul Rothman | Merck Company | 63 | |
| Malcolm McAvity | Dorian LPG | 69 | |
| Shantanu Narayen | Pfizer Inc | 57 | |
| Ronald Blaylock | Pfizer Inc | 61 | |
| Nina Vaca | Cinemark Holdings | 49 | |
| Peter Bacchus | Gold Fields Ltd | 51 | |
| Helen Hobbs | Pfizer Inc | 68 | |
| Leslie Brun | Merck Company | 68 | |
| Susan Hockfield | Pfizer Inc | 70 | |
| Terence Goodlace | Gold Fields Ltd | 60 | |
| Steve Reid | Gold Fields Ltd | 63 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.084 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| A Washington, Independent Director | ||
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman, CEO, Chairman of Executive Committee and Chairman of Fin. Committee | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Elizabeth JD, Executive Officer | ||
| Duane Arsdale, Treasurer | ||
| Michael Ullmann, VP, General Counsel and Member of Executive Committee | ||
| Jasmina Brooks, President Webster | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Executive CFO | ||
| Michael Bodner, Global Recovery | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Mary Beckerle, Independent Director | ||
| Nadja West, Independent Director | ||
| Mark Larkins, Worldwide Secretary | ||
| Darius Adamczyk, Independent Director | ||
| Vanessa Broadhurst, Executive Vice President Global Corporate Affairs | ||
| Hani Abouhalka, Company Digital | ||
| Ahmet Tezel, Group RD | ||
| Robert Decker, Controller Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Mathai Mammen, Executive Vice President Pharmaceuticals, R&D | ||
| Timothy Schmid, Executive MedTech | ||
| Ronald Williams, Independent Director | ||
| Tom Cavanaugh, Company Medicine | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| William Hait, Executive Vice President Chief External Innovation, Medical Safety, Global Public Health Officer | ||
| James Swanson, Executive Vice President, Chief Information Officer | ||
| D Davis, Independent Director | ||
| Hubert Joly, Independent Director | ||
| Anne Mulcahy, Lead Independent Director | ||
| Joseph Wolk, Chief Financial Officer, Executive Vice President | ||
| Thibaut Mongon, Executive Vice President, Worldwide Chairman, Consumer Health | ||
| Jessica Moore, Vice Relations | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Worldwide Chairman of Pharmaceuticals, Chief Scientific Officer and Member of Executive Committee | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Celine Martin, Group CSS | ||
| Elizabeth Forminard, Executive Counsel | ||
| Peter Fasolo, Chief Human Resource Officer, Executive Vice President | ||
| Guy MD, Group EMEA | ||
| Mark Weinberger, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.084 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 384.09 B | ||||
| Shares Outstanding | 2.41 B | ||||
| Shares Owned By Insiders | 0.09 % | ||||
| Shares Owned By Institutions | 72.97 % | ||||
| Number Of Shares Shorted | 18.11 M | ||||
| Price To Earning | 24.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Johnson Stock please use our How to buy in Johnson Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Johnson Johnson. If investors know Johnson will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Johnson Johnson listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.89) | Dividend Share 4.86 | Earnings Share 6.05 | Revenue Per Share 36.428 | Quarterly Revenue Growth 0.052 |
The market value of Johnson Johnson is measured differently than its book value, which is the value of Johnson that is recorded on the company's balance sheet. Investors also form their own opinion of Johnson Johnson's value that differs from its market value or its book value, called intrinsic value, which is Johnson Johnson's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Johnson Johnson's market value can be influenced by many factors that don't directly affect Johnson Johnson's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Johnson Johnson's value and its price as these two are different measures arrived at by different means. Investors typically determine if Johnson Johnson is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Johnson Johnson's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.